4D Molecular Therapeutics (NASDAQ:FDMT) Releases Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Key Points

• 4D Molecular Therapeutics reported an earnings per share (EPS) of ($0.98), which missed analysts' estimates by ($0.29).
• Despite a negative return on equity of 33.26% and a significant negative net margin, institutional investors hold 99.27% of the company's stock.
• Analysts have a Moderate Buy average rating for the stock, with price targets ranging from $25.00 to $51.00, indicating varied investor sentiment.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) released its earnings results on Monday. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10), Zacks reports. 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.52 million.

4D Molecular Therapeutics Price Performance

NASDAQ:FDMT traded up $0.08 on Friday, reaching $7.18. The stock had a trading volume of 201,110 shares, compared to its average volume of 877,249. The company has a market cap of $335.31 million, a price-to-earnings ratio of -2.01 and a beta of 2.83. The firm's fifty day moving average is $4.62 and its two-hundred day moving average is $4.13. 4D Molecular Therapeutics has a 12-month low of $2.23 and a 12-month high of $17.41.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday. Barclays lowered their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a report on Friday, May 9th. The Goldman Sachs Group decreased their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a report on Friday, May 9th. Chardan Capital reissued a "buy" rating and issued a $25.00 price objective on shares of 4D Molecular Therapeutics in a report on Tuesday. Finally, Roth Capital decreased their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Tuesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $30.40.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd acquired a new stake in 4D Molecular Therapeutics in the 1st quarter worth about $39,000. AQR Capital Management LLC acquired a new stake in 4D Molecular Therapeutics in the 1st quarter worth about $46,000. Russell Investments Group Ltd. boosted its stake in 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company's stock worth $81,000 after buying an additional 2,284 shares during the last quarter. Bridgeway Capital Management LLC boosted its stake in 4D Molecular Therapeutics by 100.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 25,000 shares of the company's stock worth $93,000 after buying an additional 12,516 shares during the last quarter. Finally, Sei Investments Co. acquired a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at about $106,000. 99.27% of the stock is owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.